Suppr超能文献

儿童在产前暴露于抗抑郁药后注意缺陷/多动障碍:来自挪威母婴队列研究的结果。

Attention-deficit/hyperactivity disorder in children following prenatal exposure to antidepressants: results from the Norwegian mother, father and child cohort study.

机构信息

PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, 0316, Norway.

Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, 0213, Norway.

出版信息

BJOG. 2021 Nov;128(12):1917-1927. doi: 10.1111/1471-0528.16743. Epub 2021 Jun 8.

Abstract

OBJECTIVE

To determine the association between child attention-deficit/hyperactivity disorder (ADHD) and prenatal exposure to selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitor antidepressants, by timing and duration, with quantification of bias due to exposure misclassification.

DESIGN

Norwegian Mother, Father and Child Cohort Study and national health registries.

SETTING

Nationwide, Norway.

POPULATION

A total of 6395 children born to women who reported depression/anxiety in pregnancy and were either medicated with SSRI/SNRI in pregnancy (n = 818) or non-medicated (n = 5228), or did not report depression/anxiety but used antidepressants 6 months before pregnancy (discontinuers, n = 349).

MAIN OUTCOME MEASURE

Diagnosis of ADHD or filled prescription for ADHD medication in children, and mother-reported symptoms of ADHD by child age 5 years.

RESULTS

When the hazard was averaged over the duration of the study follow up, there was no difference in ADHD risk between ever in utero SSRI/SNRI-exposed children and comparators (weighted hazard ratio [wHR] 1.07, 95% CI 0.76-1.51 versus non-medicated; wHR 1.53, 95% CI 0.77-3.07 versus discontinuers). Underestimation of effects due to exposure misclassification was modest. In early childhood, the risk for ADHD was lower with prenatal SSRI/SNRI exposure compared with no exposure, and so were ADHD symptoms (weighted β -0.23, 95% CI -0.39 to -0.08); this risk became elevated at child age 7-9 years (wHR 1.93, 95% CI 1.22-3.05). Maternal depression/anxiety before pregnancy was independently associated with child ADHD.

CONCLUSION

Prenatal SSRI/SNRI exposure is unlikely to considerably increase the risk of child ADHD beyond that posed by maternal depression/anxiety. The elevated risk at child age 7-9 years needs to be elucidated.

TWEETABLE ABSTRACT

Women with depression who use antidepressants in pregnancy do not have greater risk of having children with ADHD. Findings in school-age children needs follow up.

摘要

目的

通过时间和持续时间,确定儿童注意缺陷多动障碍(ADHD)与产前暴露于选择性 5-羟色胺(SSRI)和 5-羟色胺-去甲肾上腺素(SNRI)再摄取抑制剂抗抑郁药之间的关联,并量化因暴露错误分类而导致的偏倚。

设计

挪威母婴儿童队列研究和国家健康登记处。

地点

全国范围,挪威。

人群

共有 6395 名儿童出生于报告孕期抑郁/焦虑的女性,她们在孕期中使用 SSRI/SNRI(n=818)或未使用药物(n=5228),或未报告抑郁/焦虑但在怀孕前 6 个月使用抗抑郁药(停药者,n=349)。

主要观察指标

儿童 ADHD 诊断或 ADHD 药物处方,以及儿童 5 岁时母亲报告的 ADHD 症状。

结果

当危险度平均分配给研究随访期间的持续时间时,宫内 SSRI/SNRI 暴露儿童与对照组之间的 ADHD 风险无差异(加权危险比[wHR]1.07,95%CI0.76-1.51 与未用药者相比;wHR1.53,95%CI0.77-3.07 与停药者相比)。因暴露错误分类而导致的低估效应较为适中。在儿童早期,与无暴露相比,产前 SSRI/SNRI 暴露与 ADHD 风险较低,ADHD 症状也较低(加权β-0.23,95%CI-0.39 至-0.08);这种风险在儿童 7-9 岁时升高(wHR1.93,95%CI1.22-3.05)。母亲在怀孕前的抑郁/焦虑与儿童 ADHD 独立相关。

结论

产前 SSRI/SNRI 暴露不太可能使儿童 ADHD 的风险显著高于母亲抑郁/焦虑的风险。需要进一步阐明 7-9 岁儿童的风险增加问题。

推文摘要

患有抑郁症的孕妇在怀孕期间使用抗抑郁药并不会增加其子女患 ADHD 的风险。在学龄儿童中发现的结果需要进一步跟踪。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验